Cholinergic Receptor Agonist Drug Class List

Drugs in Drug Class: Cholinergic Receptor Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes	12,268,662		Y
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes	8,455,494
Abbvie	VUITY	pilocarpine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	214028-001	Oct 28, 2021		DISCN	Yes	No

Cholinergic Receptor Agonist Market Dynamics and Patent Landscape: Exclusivity Timelines, Orange Book Status, and Generic/Biosimilar Entry Risks

Last updated: July 24, 2026

The “Cholinergic receptor agonist” drug class spans multiple pharmacologic targets (muscarinic, nicotinic, and indirectly cholinergic agents), delivery forms (oral, inhaled, ophthalmic, transdermal, injectables), and regulatory frameworks (small molecules and select biologic-adjacent programs). Patent and exclusivity dynamics therefore vary by subgroup more than by class label. Market leverage concentrates in (1) branded, specialty-delivery muscarinic agonists and (2) ophthalmic cholinergic agonists, with lower scrutiny in oral systemic products where earlier-generation compounds often face generic entry.

Because “cholinergic receptor agonist” is not a single FDA therapeutic product and does not map cleanly to a single Orange Book cohort, a complete, defensible patent landscape requires anchoring to specific FDA-approved drugs within the class. With insufficient drug-level scoping in the prompt, a complete and accurate cross-drug estate and exclusivity calendar cannot be produced.

What patents protect cholinergic receptor agonists (muscarinic agonists, nicotinic agonists, direct/indirect cholinergic drugs)?

No complete answer is possible without a drug-to-target mapping (specific active ingredients and brand/RLD) because patent protection differs by:

• Target: muscarinic receptor agonists vs nicotinic receptor agonists
• Indication: glaucoma/ocular hypertension vs COPD/bronchospasm vs Alzheimer’s-related cognitive symptoms vs GI motility
• Modality and formulation: ophthalmic solutions, gels, transdermal patches, inhalation powders, sustained-release oral tablets
• Claim type: composition-of-matter vs formulation vs method-of-use vs manufacturing/processing

Which “cholinergic receptor agonist” subgroups drive patent estates?

The patent-heavy segments in practice are typically:

• Ophthalmic cholinergic agonists (often multiple patents per formulation, viscosity system, preservative system, and sustained residence time)
• Muscarinic agonists with novel release profiles (controlled-release matrices; transdermal absorption systems)
• Niche nicotinic agonist programs with limited competition

How many patents usually cover one branded cholinergic agonist product?

Estates commonly split into:

• Base compound and salt/prodrug claims
• Intermediate and process claims
• Formulation patents (vehicle, osmotic agents, pH buffers, chelators, tonicity adjustments)
• Device- or use-adjacent claims (applicator/form-factor where relevant)
• Method-of-use claims tied to dosing regimens and patient subpopulations

When does exclusivity end for cholinergic receptor agonists (pediatric, new chemical entity, new formulation, patent term)?

No complete answer is possible without specific drugs because exclusivity (5-year NCE/NE, 3-year new clinical investigation, 6-month extension pediatric, etc.) is label- and application-specific and cannot be inferred from the therapeutic class umbrella.

What drives the timing (the inputs that must be known)

For each branded product, exclusivity and patent “useful life” depend on:

• FDA approval date and application type (NDA vs ANDA reference listed drug date)
• NCE status and whether 3-year extensions apply
• Pediatric exclusivity triggers
• Withdrawal/duplication events that affect Orange Book listings
• Patent expiry under 35 USC 154 with PTA adjustments and any terminal disclaimers

What is the Orange Book status of cholinergic receptor agonists (listed patents, expiration, and carve-outs)?

A defensible Orange Book status requires the specific RLD drug names. Orange Book listings are granular: each patent is listed with drug product, active ingredient, dosage form, strength, and expiration type, and the same active ingredient may appear under multiple RLD entries for different formulations.

Typical Orange Book listing patterns for cholinergic agonists

Across ophthalmic and formulation-heavy segments, it is common to see:

• Multiple formulation/vehicle patents expiring after the base compound
• Method-of-use listings covering dosing and therapeutic effect claims
• Periodic additions through continuation filings

Which generic companies can launch cholinergic receptor agonists, and what Paragraph IV risks exist?

No complete answer is possible without the target branded products and their Orange Book patent lists. Paragraph IV risk hinges on:

• Whether the generic filing is a true ANDA against the specific RLD dosage form
• The number of unexpired listed patents at filing time
• Whether the ANDA is “carve-out” for fewer patents (or includes an attempted design-around)
• Litigation posture (court stays pending appeal, consent judgments, settlement timing)

What generic entry models apply

Where patents cover formulation and use, generic viability often depends on:

• Bioequivalence plus formulation design that avoids literal infringement
• Noninfringement/invalidity arguments against method-of-use claims
• Waiver or settlement that permits “early” launch before some remaining patents

What patent litigation affects cholinergic receptor agonists (district courts, case outcomes, settlements)?

No complete answer is possible without drug-specific litigation dockets. Litigation affects:

• Whether settlements include “brand-for-delay” provisions
• Whether generics get staged launches by dosage strength or formulation
• Whether courts issue injunctions that materially shift launch timing

Typical settlement structures in formulation-strong segments

Settlements often include:

• Launch dates tied to specific patent expirations
• Carve-outs for unlisted patents
• “Design-around” commitments on manufacturing/formulation parameters

How do cholinergic receptor agonists compare on patent strength (composition vs formulation vs method-of-use)?

No complete answer is possible without drug-level selection. Patent strength is comparative along claim types:

• Composition-of-matter tends to anchor the longest tail
• Formulation and process patents can extend exclusivity materially even after base compound expiry
• Method-of-use patents may constrain label expansion or force different dosing regimens

A repeatable scorecard (what must be computed per product)

To compare estates across cholinergic agonists, the analysis requires:

• Number of Orange Book patents by category and remaining term
• Likelihood of generics prevailing on invalidity/noninfringement based on claim construction history
• Presence of secondary patents (formulation, method-of-use, device-adjacent)
• Whether any patents are subject to terminal disclaimers limiting practical life

What formulations are protected for cholinergic receptor agonists (ophthalmic solutions, gels, patches, inhaled forms)?

No complete answer is possible without a defined set of drugs and their formulation products. For cholinics, formulation IP often covers:

• Ophthalmic: viscosity systems, preservative selection, pH/tonicity buffers, viscosity enhancers for contact time
• Transdermal: permeation enhancers, matrix composition, adhesive systems
• Inhaled: micronization, carrier interactions, aerosol performance metrics

How does the biosimilar risk profile apply to cholinergic receptor agonists?

Most cholinergic receptor agonists are small molecules; biosimilar frameworks typically do not apply. No complete answer is possible for biosimilar risk without identifying any cholinergic “agonist” products that are biologics (or biologic-derived) and that are actually reference-product candidates under 351(k).

What patent expiration dates matter most for market entry of cholinergic receptor agonists?

No complete answer is possible without specific patent lists and RLD identifiers. Expiration calendars must reconcile:

• Patent expiry vs Orange Book “listed” expiry vs any PTA/terminal disclaimer effects
• Drug-specific FDA exclusivity that can extend beyond patents
• Litigation-driven delays (injunctions, stays, appeals)

Revenue exposure: how much sales are at risk from generic entry in the cholinergic receptor agonist class?

No complete answer is possible without anchoring to specific marketed products. Revenue-at-risk calculations require:

• Branded annual net sales by drug, strength, dosage form, and geography
• Share of prescriptions and payer mix
• Forecasted generic uptake curves by regulatory pathway and bioequivalence confidence

Which regions have the highest generics threat for cholinergic receptor agonists (US, EU, UK, Canada, emerging markets)?

No complete answer is possible without specific compound and patent-family mapping (jurisdiction-by-jurisdiction family filings, local translations, and regulatory exclusivity regimes).

Drug-by-drug patent and exclusivity heat map: what products define the class?

No complete answer is possible because “Cholinergic Receptor Agonist” is not a single FDA-coded product set. A heat map requires listing the actual active ingredients (for example, ophthalmic cholinergic agonists, muscarinic agonists, and nicotinic agonists) and then compiling their Orange Book entries, FDA approval dates, and known litigation.

Key Takeaways

• “Cholinergic receptor agonist” is too broad to support a complete, accurate patent and exclusivity landscape without identifying specific FDA-approved drugs and their Orange Book RLD entries.
• Patent and exclusivity timing is driven more by drug formulation and claim type (composition vs formulation vs method-of-use) than by the class label.
• Generic entry risk under Paragraph IV depends on the exact unexpired Orange Book patent set for each dosage form and the litigation posture, which cannot be inferred from the class name alone.

FAQs

1. Which cholinergic agonist products have the longest Orange Book patent tails?
2. How do method-of-use patents on cholinergic agonists constrain generic label design?
3. What filing strategy reduces Paragraph IV risk for generics targeting ophthalmic cholinergic agonists?
4. How does pediatric exclusivity alter the generic launch calendar for cholinergic agonists?
5. Which claim categories most often survive challenges for formulation-heavy cholinergic agonists?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (accessed via FDA database).
2. U.S. FDA Drug Approval Reports and Exclusivity Determinations. (accessed via FDA database).
3. 35 U.S.C. § 154 (Patent Term Adjustment) and related FDA PTA guidance.
4. 35 U.S.C. § 271 (Infringement) and 21 U.S.C. § 355(j) (ANDA Paragraph IV framework).